Secukinumab Efficacy Without the Initial Loading Dose in Patients With Psoriasis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03828643|
Recruitment Status : Not yet recruiting
First Posted : February 4, 2019
Last Update Posted : February 4, 2019
|Condition or disease||Intervention/treatment|
|Psoriasis Vulgaris||Drug: Secukinumab|
|Study Type :||Observational|
|Estimated Enrollment :||156 participants|
|Official Title:||Secukinumab Efficacy Without the Initial Loading Dose at Weeks 0, 1, 2, 3 and 4 in Patients With Chronic Plaque Psoriasis|
|Estimated Study Start Date :||February 2019|
|Estimated Primary Completion Date :||May 2019|
|Estimated Study Completion Date :||July 2019|
Cases received secukinumab at the dose 300 mg every 4 weeks from the beginning.
Secukinumab 300 mg without loading dose at weeks 0, 1, 2, 3 and 4.
Controls received secukinumab at the dose 300 mg with loading dose at weeks 0, 1, 2, 3 and 4, followed by monthly maintenance dosing.
Secukinumab 300 mg with loading dose at weeks 0, 1, 2, 3 and 4.
- PASI75 [ Time Frame: week 48 ]
- PASI90 [ Time Frame: week 48 ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03828643
|University of Verona||Recruiting|
|Verona, Italy, 37126|
|Contact: Paolo Gisondi, MD 045-8122647 ext 0039 email@example.com|
|Sub-Investigator: Paolo Gisondi, MD|